Navigation Links
Colorectal cancer risk increases in prostate cancer patients on androgen deprivation therapy
Date:11/10/2010

Men taking androgen deprivation therapy (ADT) for prostate cancer may have an increased risk of colorectal cancer, according to a study published online November 10 in The Journal of the National Cancer Institute.

Androgen deprivation therapy is a widely-prescribed treatment in men with prostate cancer, although its usage for low-risk disease remains controversial, given the adverse side effects, including osteoporosis, cardiovascular disease, diabetes and obesity; the last two are risk factors for colorectal cancer.

To determine whether prostate cancer patients taking androgen deprivation therapy are at an increased risk of colon cancer, Silke Gillessen, M.D., of the Cantonal Hospital in St. Gallen, Switzerland, and colleagues, did an observational study of men with prostate cancer identified through the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Specifically, they identified 107,859 men aged 67 years or older who were diagnosed with prostate cancer between 1993 and 2002, with follow-up through 2004. The men received the ADT either in the form of gonadotropin-releasing hormone (GnRH) agonists, or an orchiectomy.

The researchers found that after adjustment for confounding variables such as age and socio-economic status, there was a 30-40% relative increase in the rate of colorectal cancer among the men treated with ADT compared with those who were not. Furthermore, the longer the men took ADT, the greater their risk of developing colorectal cancer. However, further study would be needed to determine the risk with treatment over longer periods than could be observed in this study.

The authors write that the study results could have "important implications" for men with prostate cancer taking ADT, especially those with localized, slow-growing disease, for whom the duration of ADT is generally longer.

In an accompanying editorial, Jennifer H. Lin, Ph.D., and Edward Giovannucci, M.D., of Brigham and Women's Hospital in Boston write that the study shows that an elevated risk of colorectal cancer may be an additional consideration in the decision to use ADT, especially given the side effects and their effect on quality of life.


'/>"/>

Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Statins did not reduce colorectal cancer in WHI analysis
2. Colorectal cancer survival advantage in MUTYH-associated polyposis
3. Healthy Living Can Prevent Nearly 25% of Colorectal Cancers
4. Colorectal cancer patients with gene mutation show better response to cancer agent
5. Colorectal cancer screening can be expanded by offering it during mammography visits
6. Virtual colonoscopy option could improve colorectal cancer screening rates, patient survey suggests
7. Virtual colonoscopy and teleradiology bring colorectal cancer screening to patients in rural areas
8. Type 2 diabetes and insulin use are associated with colorectal cancer in men
9. Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer
10. Lack of insurance coverage remains obstacle to wider colorectal cancer screening with CT colonography
11. Colorectal cancer screening in Canada is cost-effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the launch ... and easy access to essential information that offers a more comprehensive understanding of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Renal ... for people who have kidney disease. The theme “Describe a positive decision that ... Entrants needed to meet only one qualification— to have been diagnosed with ...
(Date:9/20/2017)... Houston, TX (PRWEB) , ... September 20, 2017 ... ... the date of the much-anticipated fall event , Look Awesome This Autumn ... demonstrations, personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of ... recently unveiled a redesigned website. The new site – still located at ... architects, contractors and other industry users that Garland serves. , After an ambitious ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time since going on ... positive feedback from customers trying the product for the first time, and others who ... developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at risk from multiple ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: